Earnings Feed
Start Free
Home/Filings/4/0001178913-23-002370
4//SEC Filing

Darvish Nissim 4

Accession 0001178913-23-002370

CIK 0001534248other
View on SEC.govCompany Profile

Filed

Jul 4, 8:00 PM ET

Accepted

Jul 5, 5:48 PM ET

Size

16.7 KB

Accession

0001178913-23-002370

Insider Transaction Report

Form 4
Period: 2023-06-14
Chemomab Therapeutics Ltd.CMMB
Darvish Nissim
Director
Transactions
  • Award

    Option to Purchase American Depositary Shares

    2023-03-16+6,857→ 6,857 total
    Exercise: $1.62Exp: 2033-03-21→ American Depositary Shares (6,857 underlying)
  • Award

    Option to Purchase American Depositary Shares

    2016-10-28+10,123→ 10,123 total
    Exercise: $0.80Exp: 2017-10-27→ American Depositary Shares (10,123 underlying)
  • Award

    Option to Purchase American Depositary Shares

    2022-03-07+6,820→ 6,820 total
    Exercise: $3.53Exp: 2032-03-07→ American Depositary Shares (6,820 underlying)
  • Award

    Option to Purchase American Depositary Shares

    2023-06-14+20,572→ 20,572 total
    Exercise: $1.70Exp: 2033-06-14→ American Depositary Shares (20,572 underlying)
  • Award

    Option to Purchase American Depositary Shares

    2021-04-19+11,884→ 11,884 total
    Exercise: $27.26Exp: 2031-04-19→ American Depositary Shares (11,884 underlying)
Holdings

  • American Depositary Shares

    1,200
Footnotes (7)
  • [F1]No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.
  • [F2]Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.
  • [F3]These options vest and become exercisable in equal monthly installments over a 36 month period, subject to the Reporting Person's continued service.
  • [F4]These options were granted as per the annual grant of options to directors. These options vest and become exercisable in their entirety on March 16, 2024, subject to the Reporting Person's continued service.
  • [F5]These options vested and became exercisable in their entirety on March 16, 2023. These options were granted as per the annual grant of options to directors.
  • [F6]These options vest and become exercisable in equal monthly installments over a 36 month period commencing on March 16, 2021, subject to the Reporting Person's continued service.
  • [F7]The options reported in this row have all vested and are exercisable as of the date hereof, subject to the Reporting Person's continued service.

Documents

1 file

Issuer

Chemomab Therapeutics Ltd.

CIK 0001534248

→
Entity typeother

Related Parties

1
  • filerCIK 0001793602

Filing Metadata

Form type
4
Filed
Jul 4, 8:00 PM ET
Accepted
Jul 5, 5:48 PM ET
Size
16.7 KB
View on SEC.gov